Insider Transactions Reported by 55 Insiders of Keenova Therapeutics plc

Location: Dublin 15

Quick Takeaways

Keenova Therapeutics plc has 55 insiders with reported activity on this page.
Net insider value flow over the last year: +$75,479,692.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $75,479,692; sell value: $0.
Net share flow: +825,674.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$75,479,692.

Buys

$75,479,692

Shares: 825,674

Insiders: 2

Sells

Shares: 0

Insiders: 0

Net

+$75,479,692

Shares: +825,674

Insiders: 2

Window (months)	Buy shares	Buy $	Sell $	Net $
0-3	0	$0	$0	$0
3-6	422,974	$38,419,192	$0	+$38,419,192
6-9	316,000	$29,498,250	$0	+$29,498,250
9-12	86,700	$7,562,250	$0	+$7,562,250

Keenova Therapeutics plc executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
GOLDENTREE ASSET MANAGEMENT LP	10%+ Owner	$736,139,041	+$7,562,250	+1%	Mixed	04 Aug 2025
Robert J. O'Shea	10%+ Owner	$520,079,117			Mixed	15 Apr 2026
Edward A. Mule	10%+ Owner	$520,079,117			Mixed	15 Apr 2026
Silver Point Capital L.P.	10%+ Owner	$456,887,866	+$67,917,443	+17%	Mixed	15 Apr 2026
Alta Fundamental Advisers LLC	10%+ Owner	$73,015,988			Mixed	16 Jun 2023
Olafsson Sigurdur O	President and CEO, Director	$2,814,973			Mixed	25 Feb 2026
Christiana Stamoulis	President and CFO	$1,582,235			Mixed	25 Feb 2026
David J. Stetson	Director	$1,001,497			Mixed	31 Jul 2025
Wesley Wheeler	Director	$869,585			Mixed	31 Jul 2025
Abbas Hussain	Director	$846,230			Mixed	31 Jul 2025
Paul Efron	Director	$781,319			Mixed	23 Feb 2026
Lisa French	EVP & Chief Commercial Officer	$744,613			Mixed	25 Feb 2026
Mark Anthony Tyndall	EVP & CLO and Corp Sec	$724,821			Mixed	25 Feb 2026
Jon Zinman	Director	$712,751			Mixed	23 Feb 2026
Henriette Nielsen	EVP & Chief Transformation OFC	$668,998			Mixed	25 Feb 2026
Bradley Mark T.	EVP, Chief Integration Officer	$371,431			Mixed	31 Jul 2025
Paul Bisaro	Director	$370,798			Mixed	23 Feb 2026
Katina Dorton	Director	$222,319			Mixed	23 Feb 2026
Hugh Paul ONeill	EVP, Chief Operations Officer	$159,928			Mixed	25 Feb 2026
Sophia D. Langlois	Director	$68,768			Mixed	23 Feb 2026
Marc J. Yoskowitz	Director	$68,076			Mixed	23 Feb 2026
Tracy Basso	Evp & Chro	$67,643			Mixed	23 Apr 2026
Susan Ann Williamson	EVP & Chief Compliance Officer	$62,799			Mixed	23 Apr 2026
Cheryl Ann Stouch	EVP & Chief Info Officer	$54,582			Mixed	23 Apr 2026
Scott Hirsch	Director	$39,358			Mixed	23 Feb 2026
Leslie E. Donato	Director				Mixed	23 Feb 2026
Marek Honczarenko	EVP, Chief Scientific Officer				Mixed	25 Feb 2026
Kassie Harrold	EVP & Chief Compliance Officer				Mixed	01 Jan 2025
Carlos Paya V	Director				Mixed	16 Jun 2022
James R. Sulat	Director				Mixed	14 Nov 2023
Steven J. Romano	EVP & Chief Sci. Ofcr				Mixed	16 Jun 2022
Paul Rutherford Carter	Director				Mixed	16 Jun 2022
Daniel Arthur Celentano	Director				Mixed	14 Nov 2023
Riad El-Dada	Director				Mixed	14 Nov 2023
J. Martin Carroll	Director				Mixed	16 Jun 2022
Peter C. Richardson	EVP & Chief Scientific Officer				Mixed	31 Jul 2025
Karen Ling	Director				Mixed	14 Nov 2023
Ian J. Watkins	EVP & Chief Human Resources Officer				Mixed	16 Jun 2022
Woodrow A. Myers Jr.	Director				Mixed	14 Nov 2023
Mark Trudeau	President and CEO, Director				Mixed	16 Jun 2022
Joann A. Reed	Director				Mixed	16 Jun 2022
Mark J. Casey	EVP & Chief Legal Officer				Mixed	16 Jun 2022
Bryan M. Reasons	Evp & Cfo				Mixed	31 Jul 2025
Jason Daniel Goodson	EVP & Chief Strategy Officer				Mixed	01 Jan 2025
Hugh M. O'Neill	EVP & Chief Comm and Ops Ofcr				Mixed	16 Jun 2022
Stephen Andrew Welch	EVP & Head of Spec Generics				Mixed	10 Nov 2025
Angus C. Russell	Director				Mixed	16 Jun 2022
David Y. Norton	Director				Mixed	16 Jun 2022
Neal P. Goldman	Director				Mixed	14 Nov 2023
Susan Michele Silbermann	Director				Mixed	14 Nov 2023
Anne Clem Whitaker	Director				Mixed	16 Jun 2022
Dr Kneeland Youngblood	Director				Mixed	16 Jun 2022
Bracebridge Capital, LLC	10%+ Owner				Mixed	14 Nov 2023
David R. Carlucci	Director				Mixed	16 Jun 2022
Frank B. Raciti	Controller & CAO				Mixed	19 Aug 2025

Top shareholders of Keenova Therapeutics plc (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
GOLDENTREE ASSET MANAGEMENT LP	3/4/5 13D/G	10%+ Owner · Steven A. Tananbaum	20% from 13D/G	7,979,827	$736,139,041	+$7,562,250	04 Aug 2025	3/4/5 13D/G
Edward A. Mule	3/4/5	10%+ Owner	14%	5,637,714	$520,079,117	—	15 Apr 2026	3/4/5
Robert J. O'Shea	3/4/5	10%+ Owner	14%	5,637,714	$520,079,117	—	15 Apr 2026	3/4/5
Silver Point Capital L.P.	3/4/5 13D/G	10%+ Owner	14% from 13D/G	5,637,714	$456,887,866	+$67,917,443	15 Apr 2026	3/4/5 13D/G
Alta Fundamental Advisers LLC	3/4/5	10%+ Owner	— class O/S missing	1,947,093	$73,015,988	—	16 Jun 2023	3/4/5
Olafsson Sigurdur O	3/4/5	President and CEO, Director	— mixed-class rows	538,533 mixed-class rows	$2,814,973	—	25 Feb 2026	3/4/5
Christiana Stamoulis	3/4/5	President and CFO	— mixed-class rows	192,009 mixed-class rows	$1,582,235	—	25 Feb 2026	3/4/5
David J. Stetson	3/4/5	Director	0.03%	11,578	$1,001,497	—	31 Jul 2025	3/4/5
Wesley Wheeler	3/4/5	Director	0.03%	10,053	$869,585	—	31 Jul 2025	3/4/5
Abbas Hussain	3/4/5	Director	0.02%	9,783	$846,230	—	31 Jul 2025	3/4/5
Paul Efron	3/4/5	Director	— mixed-class rows	18,959 mixed-class rows	$781,319	—	23 Feb 2026	3/4/5
Lisa French	3/4/5	EVP & Chief Commercial Officer	— mixed-class rows	106,215 mixed-class rows	$744,613	—	25 Feb 2026	3/4/5
Mark Anthony Tyndall	3/4/5	EVP & CLO and Corp Sec	— mixed-class rows	105,992 mixed-class rows	$724,821	—	25 Feb 2026	3/4/5
Jon Zinman	3/4/5	Director	— mixed-class rows	47,585 mixed-class rows	$712,751	—	23 Feb 2026	3/4/5
Henriette Nielsen	3/4/5	EVP & Chief Transformation OFC	— mixed-class rows	105,363 mixed-class rows	$668,998	—	25 Feb 2026	3/4/5
Bradley Mark T.	3/4/5	EVP, Chief Integration Officer	— mixed-class rows	61,895 mixed-class rows	$371,431	—	31 Jul 2025	3/4/5
Paul Bisaro	3/4/5	Director	— mixed-class rows	51,403 mixed-class rows	$370,798	—	23 Feb 2026	3/4/5
Katina Dorton	3/4/5	Director	— mixed-class rows	34,387 mixed-class rows	$222,319	—	23 Feb 2026	3/4/5
Hugh Paul ONeill	3/4/5	EVP, Chief Operations Officer	— mixed-class rows	50,715 mixed-class rows	$159,928	—	25 Feb 2026	3/4/5
Sophia D. Langlois	3/4/5	Director	— mixed-class rows	9,661 mixed-class rows	$68,768	—	23 Feb 2026	3/4/5
Marc J. Yoskowitz	3/4/5	Director	— mixed-class rows	12,608 mixed-class rows	$68,076	—	23 Feb 2026	3/4/5
Tracy Basso	3/4/5	EVP & CHRO	— mixed-class rows	49,022 mixed-class rows	$67,643	—	23 Apr 2026	3/4/5
Susan Ann Williamson	3/4/5	EVP & Chief Compliance Officer	— mixed-class rows	28,409 mixed-class rows	$62,799	—	23 Apr 2026	3/4/5
Cheryl Ann Stouch	3/4/5	EVP & Chief Info Officer	— mixed-class rows	26,800 mixed-class rows	$54,582	—	23 Apr 2026	3/4/5
Scott Hirsch	3/4/5	Director	— mixed-class rows	9,321 mixed-class rows	$39,358	—	23 Feb 2026	3/4/5
MARATHON ASSET MANAGEMENT LP	13D/G	MARATHON ASSET MANAGEMENT GP, L.L.C.	6.8%	2,710,229	—	$0	31 Mar 2026	13D/G
Hein Park Capital Management LP	13D/G	—	5.5%	2,146,733	—	$0	31 Dec 2025	13D/G
Hudson Bay Capital Management LP	13D/G	—	5.2%	2,049,739	—	$0	31 Dec 2025	13D/G
Bracebridge Capital, LLC	3/4/5	10%+ Owner	— class O/S missing	1,093,857	—	—	14 Nov 2023	3/4/5
James E. Flynn	13D/G	Deerfield Management Company, L.P.	4.1%	804,259	—	$0	31 Mar 2025	13D/G
Bryan M. Reasons	3/4/5	EVP & CFO	— mixed-class rows	59,828 mixed-class rows	—	—	31 Jul 2025	3/4/5
Marek Honczarenko	3/4/5	EVP, Chief Scientific Officer	— class O/S missing	58,434	—	—	25 Feb 2026	3/4/5
Peter C. Richardson	3/4/5	EVP & Chief Scientific Officer	— mixed-class rows	30,776 mixed-class rows	—	—	31 Jul 2025	3/4/5
Jason Daniel Goodson	3/4/5	EVP & Chief Strategy Officer	— mixed-class rows	14,693 mixed-class rows	—	—	01 Jan 2025	3/4/5
Leslie E. Donato	3/4/5	Director	— class O/S missing	8,866	—	—	23 Feb 2026	3/4/5
Kassie Harrold	3/4/5	EVP & Chief Compliance Officer	— mixed-class rows	4,283 mixed-class rows	—	—	01 Jan 2025	3/4/5
Stephen Andrew Welch	3/4/5	EVP & Head of Spec Generics	— class O/S missing	3,631	—	—	10 Nov 2025	3/4/5

Recent Insider Transactions by Companies or Individuals for Keenova Therapeutics plc

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Tracy Basso	Ordinary Shares	Options Exercise	194.8%			1,523	2,305	23 Apr 2026	Direct
Tracy Basso	Restricted Stock Units	Options Exercise	-3.16%			-1,523	46,717	23 Apr 2026	Direct
Cheryl Ann Stouch	Ordinary Shares	Options Exercise	180.2%			1,137	1,768	23 Apr 2026	Direct
Cheryl Ann Stouch	Restricted Stock Units	Options Exercise	-4.34%			-1,137	25,032	23 Apr 2026	Direct
Susan Ann Williamson	Ordinary Shares	Options Exercise	179.8%			1,305	2,031	23 Apr 2026	Direct
Susan Ann Williamson	Restricted Stock Units	Options Exercise	-4.71%			-1,305	26,378	23 Apr 2026	Direct
Silver Point Capital L.P.	Common Stock	Purchase	7.84%			410,000	5,637,714	17 Apr 2026	Direct
Silver Point Capital L.P.	Common Stock	Purchase	7.84%			410,000	5,637,714	17 Apr 2026	Direct
Silver Point Capital L.P.	Common Stock	Purchase	7.84%			410,000	5,637,714	17 Apr 2026	Direct
Silver Point Capital L.P.	Common Stock	Purchase	5.55%			275,000	5,227,714	15 Apr 2026	Direct
Silver Point Capital L.P.	Common Stock	Purchase	5.55%			275,000	5,227,714	15 Apr 2026	Direct
Silver Point Capital L.P.	Common Stock	Purchase	5.55%			275,000	5,227,714	15 Apr 2026	Direct
Henriette Nielsen	Restricted Stock Units	Award	112.5%			51,794	97,825	25 Feb 2026	Direct
Marek Honczarenko	Restricted Stock Units	Award				58,434	58,434	25 Feb 2026	Direct
Lisa French	Restricted Stock Units	Award	112.5%			51,794	97,825	25 Feb 2026	Direct
Tracy Basso	Restricted Stock Units	Award	251.8%			34,528	48,240	25 Feb 2026	Direct
Susan Ann Williamson	Restricted Stock Units	Award	135.7%			15,936	27,683	25 Feb 2026	Direct
Mark Anthony Tyndall	Restricted Stock Units	Award	112.5%			51,794	97,825	25 Feb 2026	Direct
Cheryl Ann Stouch	Restricted Stock Units	Award	155.7%			15,936	26,169	25 Feb 2026	Direct
Christiana Stamoulis	Restricted Stock Units	Award	138.9%			101,262	174,181	25 Feb 2026	Direct
Hugh Paul ONeill	Restricted Stock Units	Award	240%			34,528	48,913	25 Feb 2026	Direct
Olafsson Sigurdur O	Restricted Stock Units	Award	64.4%			198,539	506,815	25 Feb 2026	Direct
Jon Zinman	Restricted Stock Units	Award	11.2%			3,984	39,554	23 Feb 2026	Direct
Marc J. Yoskowitz	Restricted Stock Units	Award	81.6%			5,312	11,821	23 Feb 2026	Direct
Sophia D. Langlois	Restricted Stock Units	Award	81.6%			3,984	8,866	23 Feb 2026	Direct
Scott Hirsch	Restricted Stock Units	Award	81.6%			3,984	8,866	23 Feb 2026	Direct
Paul Efron	Restricted Stock Units	Award	61.2%			3,984	10,494	23 Feb 2026	Direct
Katina Dorton	Restricted Stock Units	Award	14.3%			3,984	31,882	23 Feb 2026	Direct
Leslie E. Donato	Restricted Stock Units	Award	81.6%			3,984	8,866	23 Feb 2026	Direct
Paul Bisaro	Restricted Stock Units	Award	9.21%			3,984	47,225	23 Feb 2026	Direct
Silver Point Capital L.P.	Common Stock	Purchase	5.32%	$23,062,500	$92.25	250,000	4,952,714	07 Jan 2026	Direct
Jon Zinman	Ordinary Shares	Options Exercise	120.2%			4,384	8,031	01 Jan 2026	By JZ Advisors LLC
Jon Zinman	Restricted Stock Units	Options Exercise	-11%			-4,384	35,570	01 Jan 2026	Direct
Mark Anthony Tyndall	Ordinary Shares	Tax liability	-20.5%			-2,107	8,167	01 Jan 2026	Direct
Mark Anthony Tyndall	Ordinary Shares	Options Exercise	177.8%			6,576	10,274	01 Jan 2026	Direct
Mark Anthony Tyndall	Restricted Stock Units	Options Exercise	-12.5%			-6,576	46,031	01 Jan 2026	Direct
Hugh Paul ONeill	Ordinary Shares	Tax liability	-37.3%			-1,073	1,802	01 Jan 2026	Direct
Hugh Paul ONeill	Ordinary Shares	Options Exercise	250.6%			2,055	2,875	01 Jan 2026	Direct
Hugh Paul ONeill	Restricted Stock Units	Options Exercise	-12.5%			-2,055	14,385	01 Jan 2026	Direct
Olafsson Sigurdur O	Ordinary Shares	Tax liability	-34.8%			-16,939	31,718	01 Jan 2026	Direct
Olafsson Sigurdur O	Ordinary Shares	Options Exercise	208.4%			32,878	48,657	01 Jan 2026	Direct
Olafsson Sigurdur O	Restricted Stock Units	Options Exercise	-9.64%			-32,878	308,276	01 Jan 2026	Direct
Henriette Nielsen	Ordinary Shares	Tax liability	-24.1%			-2,398	7,538	01 Jan 2026	Direct
Henriette Nielsen	Ordinary Shares	Options Exercise	195.7%			6,576	9,936	01 Jan 2026	Direct
Henriette Nielsen	Restricted Stock Units	Options Exercise	-12.5%			-6,576	46,031	01 Jan 2026	Direct
Lisa French	Ordinary Shares	Tax liability	-19.1%			-1,986	8,390	01 Jan 2026	Direct
Lisa French	Ordinary Shares	Options Exercise	173%			6,576	10,376	01 Jan 2026	Direct
Lisa French	Restricted Stock Units	Options Exercise	-12.5%			-6,576	46,031	01 Jan 2026	Direct
Katina Dorton	Ordinary Shares	Tax liability	-17%			-513	2,505	01 Jan 2026	Direct
Katina Dorton	Ordinary Shares	Options Exercise	149.4%			1,808	3,018	01 Jan 2026	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.